Seite auswählen

For patients suffering from COPD (a combination of various lung diseases), the prospect of a more effective and non-injurious drug from the pharmaceutical company Novartis has been created.

They indicated that the lung drug QVA149 had proven itself in the latest clinical trials, where patients suffered significantly fewer relapses than those who received standard therapy. Therefore, the Swiss group will be applying for approval of the drug in the EU and Japan by the end of the year. For the U.S., Novartis plans to apply for release of QVA149 to the market by the end of2014.

[ilink url=““] Link zur Quelle ([/ilink]